TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37941979

Group type: EXPERIMENTAL
Intervention: Sunitinib (79% before 2018, 52% after 2018)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cabozantinib (31% after 2018)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab combination (10% after 2018)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cabozantinib (23%)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: IMDC risk category
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Second-line medical treatment
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Hospital inpatient days
Number of subjects: 336
Study: 37942277

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 4362

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily
Number of subjects: 4362

Group type: COMPARATOR
Intervention: TNFi (tumor necrosis factor inhibitors)
Number of subjects: 4362
Study: 37942314

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of AMG 212
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous intravenous (CIV) administration of AMG 212
Number of subjects: 0
Study: 37942328

Group type: EXPERIMENTAL
Intervention: 6 mg/kg cadonilimab every 2 weeks plus lenvatinib (cohort A)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 15 mg/kg cadonilimab every 3 weeks plus lenvatinib (cohort B)
Number of subjects: 59
Study: 37942487

Group type: EXPERIMENTAL
Intervention: Dual intracerebroventricular and intravitreal administration (specific dosage and duration not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific intervention not provided)
Number of subjects: 0
Study: 37942666

Group type: EXPERIMENTAL
Intervention: Titanium-zirconium (TiZr) implants
Number of subjects: 91

Group type: COMPARATOR
Intervention: Grade IV titanium (Ti) implants
Number of subjects: 91
Study: 37942680

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3700
Study: 37942723

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study: 37942793

Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 420

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 420

Group type: COMPARATOR
Intervention: No treatment (control for anticoagulation hypothesis)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No treatment (control for anti-inflammatory hypothesis)
Number of subjects: 420
Study: 37942921

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily
Number of subjects: 988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Corticosteroids at baseline
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Corticosteroids withdrawal during maintenance
Number of subjects: 988
Study: 37942930

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) treatment
Number of subjects: 35
Study: 37943075

Group type: EXPERIMENTAL
Intervention: Flavanone-rich ingredient supplementation for 16 weeks
Number of subjects: 0
Study: 37943221

Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA) suggesting guideline-recommended MRAs for eligible patients with a serum potassium of <5.0 mEq/L or novel potassium binders for those with a serum potassium of ≥5.0 mEq/L.
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA).
Number of subjects: 1210
Study: 37943223

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 37943225

Group type: EXPERIMENTAL
Intervention: ICM-based multiparameter dynamic heart failure risk score (HFRS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 136
Study: 37943227

Group type: EXPERIMENTAL
Intervention: Noom (smartphone application)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study: 37943291

Group type: EXPERIMENTAL
Intervention: Silver-triclosan graft (SynG)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard polyester graft (PolyG)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both groups (PolyG and SynG)
Number of subjects: 547
Study: 37943300

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (250 mg intravenous injection)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 37943335

Group type: EXPERIMENTAL
Intervention: Neuromodulation (noninvasive low-level tragus stimulation) 4 hours twice daily (n=8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neuromodulation (noninvasive low-level tragus stimulation)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation (n=11)
Number of subjects: 19
Study: 37943350

Group type: EXPERIMENTAL
Intervention: Cytosorb
Number of subjects: 20
Study: 37943351

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy followed by repeat local treatment (thermal ablation and/or surgical resection)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Repeat local treatment alone
Number of subjects: 360
Study: 37943362

Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 37943491

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Number of subjects: 146
Study: 37943557

Group type: EXPERIMENTAL
Intervention: Peer comparison and educational intervention for physicians and patients, including previsit emails comparing low-value testing rates and educational materials via email and text message.
Number of subjects: 314

Group type: COMPARATOR
Intervention: General previsit preparation tips for control group physicians and patients.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Peer comparison and educational intervention for physicians and patients.
Number of subjects: 314
Study: 37943580

Group type: EXPERIMENTAL
Intervention: Unsupervised therapy with an active rehabilitation robot
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Minimally supervised therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Supervised therapy
Number of subjects: 13
Study: 37943591

Group type: EXPERIMENTAL
Intervention: Supervised exergame training program at rehabilitation centers followed by a 10-week home training program under remote supervision
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 37943594

Group type: EXPERIMENTAL
Intervention: e-cigarettes (adopters) in the iCanQuit app
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: e-cigarettes (adopters) in the QuitGuide app
Number of subjects: 1562

Group type: COMPARATOR
Intervention: nonadopters in the iCanQuit app
Number of subjects: 1562

Group type: COMPARATOR
Intervention: nonadopters in the QuitGuide app
Number of subjects: 1562
Study: 37943608

Group type: EXPERIMENTAL
Intervention: Subjective socioeconomic status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective socioeconomic status
Number of subjects: 0
Study: 37943674

Group type: EXPERIMENTAL
Intervention: Behavioral activation integrated with ST (BASC) + varenicline
Number of subjects: 300

Group type: COMPARATOR
Intervention: Behavioral activation integrated with ST (BASC) + placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard behavioral cessation treatment (ST) + varenicline
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard behavioral cessation treatment (ST) + placebo
Number of subjects: 300
Study: 37944025

Group type: EXPERIMENTAL
Intervention: Retrorectus synthetic mesh
Number of subjects: 102

Group type: COMPARATOR
Intervention: Biological mesh
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both synthetic and biological mesh
Number of subjects: 102
Study: 37944074

Group type: EXPERIMENTAL
Intervention: Tretinoin (TRET; all-trans retinoic acid) with Fludarabine and Cytarabine (FLA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tretinoin (TRET; all-trans retinoic acid) with 5-azacitidine (AZA)
Number of subjects: 27
Study: 37944123

Group type: EXPERIMENTAL
Intervention: Phantasic individuals
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aphantasic individuals
Number of subjects: 34
Study: 37944528

Group type: EXPERIMENTAL
Intervention: Tepotinib (oral MET inhibitor)
Number of subjects: 24
Study: 37944541

Group type: EXPERIMENTAL
Intervention: ibrutinib-venetoclax
Number of subjects: 211

Group type: COMPARATOR
Intervention: chlorambucil-obinutuzumab
Number of subjects: 211
Study: 37944586

Group type: EXPERIMENTAL
Intervention: EuCorVac-19 (ECV-19) vaccine
Number of subjects: 197
Study: 37944925

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 51
Study: 37945063

Group type: EXPERIMENTAL
Intervention: Bilateral anterior quadratus lumborum nerve block with 60 mL ropivacaine 0.375%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo with isotonic saline injections
Number of subjects: 22
Study: 37945284

Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL) treatment
Number of subjects: 121
Study: 37945286

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD
Number of subjects: 6423

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg QD
Number of subjects: 6423

Group type: COMPARATOR
Intervention: adalimumab (RA and PsA)
Number of subjects: 6423

Group type: COMPARATOR
Intervention: methotrexate (RA)
Number of subjects: 6423

Group type: EXPERIMENTAL
Intervention: upadacitinib (both doses)
Number of subjects: 6423
Study: 37945292

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/dose, given 24-36 hours apart
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 37945297

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (500-1000 mg infusion at least 21 days prior to surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 0
Study: 37945305

Group type: EXPERIMENTAL
Intervention: E-Fit intervention (multimodal and personalised EF intervention) consisting of computer-based EF training using CogniFit Inc 2022, performed three times a week at home; weekly EF remote strategy coaching and analogue games.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group following their daily routines and completing a diary about their everyday activities four times a week.
Number of subjects: 40
Study: 37945314

Group type: EXPERIMENTAL
Intervention: Cough seconds as the unit of analysis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intralabeller agreement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interlabeller agreement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cough sound length and epoch size
Number of subjects: 24
Study: 37945311

Group type: EXPERIMENTAL
Intervention: ED clinician AAS likelihood rating
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Aortic Dissection Detection Risk Score (ADD-RS)
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: AORTAs
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Canadian clinical decision tool
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Sheffield clinical decision tool
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: CT aorta angiogram (CTA)
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Confirmed AAS diagnosis
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: AAS considered possible by ED clinician
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: AAS considered most likely by ED clinician
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: AAS considered not possible by ED clinician
Number of subjects: 5548
Study: 37945326

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS) followed by non-platinum single agent chemotherapy (paclitaxel, gemcitabine or liposomal adriamycin) for at least 4 cycles
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-platinum single agent chemotherapy
Number of subjects: 140
Study: 37945413

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (target effect-site concentrations of 0.5, 1, 2, 3, 4 ng/ml)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 74
Study: 37945419

Group type: EXPERIMENTAL
Intervention: Community pharmacist-led educational intervention and medication review
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 158
Study: 37945441

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 300
Study: 37945671

Group type: EXPERIMENTAL
Intervention: Intermittent feeding (6x/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Continuous feeding (control arm)
Number of subjects: 75
Study: 37945748

Group type: EXPERIMENTAL
Intervention: bevacizumab (bev) + olaparib (ola)
Number of subjects: 449
Study: 37945755

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone with daratumumab
Number of subjects: 0
Study: 37946117

Group type: EXPERIMENTAL
Intervention: Neurotoxic chemotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Objective assessments (biothesiometry, tuning fork, monofilament tests, Timed-Up-and-Go tests, handgrip dynamometry, 5-time repeated chair stand test)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wearable devices measuring daily gait quality and physical activity
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Weekly electronic surveys for self-reporting symptoms
Number of subjects: 200
Study: 37946122

Group type: EXPERIMENTAL
Intervention: Moderate to high intensity resistance training and aerobic training (n=44)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Aerobic training alone (n=43)
Number of subjects: 87
Study: 37946125

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based CT organ feature
Number of subjects: 208
Study: 37946136

Group type: EXPERIMENTAL
Intervention: Combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy (SBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of atezolizumab, tiragolumab, and SBRT
Number of subjects: 0
Study: 37946132

Group type: EXPERIMENTAL
Intervention: Multi-component implementation strategies including facilitation, audit and feedback, and learning collaboratives.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 26
Study: 37946167

Group type: EXPERIMENTAL
Intervention: Infant intestinal microbiota characterized by 16S and metagenomic sequencing
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Maternal milk composition
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nutrition and environment impact
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Maternal microbiome transfer
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Correlation of microbiota and maternal milk
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neuro-developmental outcomes and behavior
Number of subjects: 250
Study: 37946190

Group type: EXPERIMENTAL
Intervention: AIR + Mindfulness
Number of subjects: 100

Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 100
Study: 37946201

Group type: EXPERIMENTAL
Intervention: Mid-treatment decreases in peak PE from imaging
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Post-treatment decreases in several DCE-MRI measures
Number of subjects: 35
Study: 37946233

Group type: EXPERIMENTAL
Intervention: OEND intervention
Number of subjects: 29
Study: 37946235

Group type: EXPERIMENTAL
Intervention: Enhanced Replicating Effective Programs (REP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Implementation activities including training and implementation facilitation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Universal prevention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 8
Study: 37946256

Group type: EXPERIMENTAL
Intervention: Symptomatic patients with ATTR amyloidosis
Number of subjects: 6135

Group type: EXPERIMENTAL
Intervention: Asymptomatic gene carriers
Number of subjects: 6135
Study: 37946262

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 21
Study: 37946272

Group type: EXPERIMENTAL
Intervention: Clear protein powder shake (200 ml containing 20 g of whey protein) taken daily for the first 6 months after LRYGB.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric clear placebo shake containing maltodextrin.
Number of subjects: 0
Study: 37946283

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with nivolumab (3 mg/kg)
Number of subjects: 43
Study: 37946291

Group type: EXPERIMENTAL
Intervention: RxWell™ plus usual care (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 37946302

Group type: EXPERIMENTAL
Intervention: Deep shotgun metagenomic sequencing
Number of subjects: 215
Study: 37946314

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment, one or two sessions
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 85
Study: 37946522

Group type: EXPERIMENTAL
Intervention: Provisional stenting strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Systematic culotte stenting
Number of subjects: 200
Study: 37947096

Group type: EXPERIMENTAL
Intervention: CysC (cystatin C) measured 1 to 3 days after delivery
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CysC >75th percentile and preeclampsia
Number of subjects: 566

Group type: COMPARATOR
Intervention: CysC ≤75th percentile and no preeclampsia
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CysC only or preeclampsia only
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CysC and preterm delivery
Number of subjects: 566
Study: 37947105

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine/abacavir
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Non-abacavir regimen (bictegravir/emtricitabine/TAF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (non-HIV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: People with HIV (PWH)
Number of subjects: 37
Study: 37947140

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 699
Study: 37947157

Group type: EXPERIMENTAL
Intervention: MK-2206 150 mg weekly (escalation to 200 mg allowed)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MK-2206
Number of subjects: 16
Study: 37947177

Group type: EXPERIMENTAL
Intervention: Cardiac troponin testing
Number of subjects: 0
Study: 37947190

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) 1.3 mg/m2 body surface area subcutaneously once weekly for 8 weeks followed by oral cyclophosphamide 1 mg/kg/d for 4 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) followed by cyclophosphamide
Number of subjects: 5
Study: 37947276

Group type: EXPERIMENTAL
Intervention: Cranberry products
Number of subjects: 8857
Study: 37947315

Group type: EXPERIMENTAL
Intervention: Active GPA patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GPA patients with kidney involvement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GPA patients in remission
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GPA patients
Number of subjects: 72
Study: 37947366

Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 37947407

Group type: EXPERIMENTAL
Intervention: MRgFUS CLT
Number of subjects: 10
Study: 37947583

Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation (NESA device)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 37947856

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (imVR) rehabilitation + conventional rehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 40
Study: 37947905

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 15
Study: 37947974

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB) after neoadjuvant systemic treatment (NAST)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Routine imaging after NAST
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB)
Number of subjects: 237
Study: 37947987

Group type: EXPERIMENTAL
Intervention: FACT-GOG-Ntx (self-report measure for CIPN)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Clinical grading of CIPN by providers using the Balis Pediatric Neuropathy Scale
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measure
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: FACT-GOG-Ntx
Number of subjects: 306
Study: 37948006

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg SC per month (after a 240 mg loading dose)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Rimegepant 75 mg ODT q.o.d.
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 580

Group type: COMPARATOR
Intervention: Rimegepant
Number of subjects: 580
Study: 37948075

Group type: EXPERIMENTAL
Intervention: ED initiation of buprenorphine (intervention group)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Clinical decision support intervention (intervention group)
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 1026
Study: 37948081

Group type: EXPERIMENTAL
Intervention: A-ICU intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 159
Study: 37948113

Group type: EXPERIMENTAL
Intervention: Virtual Reality Game (VR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care using a wall TV (Control)
Number of subjects: 20